QuidelOrtho Corporation (QDEL)
NASDAQ: QDEL · Real-Time Price · USD
28.38
-0.32 (-1.11%)
Jun 27, 2025, 2:13 PM - Market open
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2014 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 30, 2025 | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | 2014 - 2020 |
Labs | 1.44B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Labs Growth | 2.22% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Point of Care | 678.30M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Point of Care Growth | -11.99% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Molecular Diagnostics | 24.40M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Molecular Diagnostics Growth | -11.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Immunohematology | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Immunohematology Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Donor Screening | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Donor Screening Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2014 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 30, 2025 | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | 2014 - 2020 |
North America Adjusted EBITDA | 907.60M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America Adjusted EBITDA Growth | 0.02% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EMEA Adjusted EBITDA | 50.20M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EMEA Adjusted EBITDA Growth | -19.94% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China Adjusted EBITDA | 135.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China Adjusted EBITDA Growth | 6.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Adjusted EBITDA | 131.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Adjusted EBITDA Growth | 4.05% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Corporate Adjusted EBITDA | -653.30M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Corporate Adjusted EBITDA Growth | 6.59% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2014 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 30, 2025 | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | 2014 - 2020 |
North America | 1.59B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America Growth | -7.85% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EMEA | 339.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EMEA Growth | 2.75% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China | 323.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China Growth | 2.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies | 508.30M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Growth | 4.14% |
Log In |
Log In |
Log In |
Log In | Upgrade
|